Can Sitagliptin reduce severe hypoglycemia risk in combination therapies by stabilizing glucose levels more effectively?
Sunil JoshiExplorer
Can Sitagliptin reduce the risk of severe hypoglycemia in combination therapies?
Share
Sitagliptin, as a DPP-4 inhibitor, enhances insulin secretion and suppresses glucagon release, thus stabilizing blood glucose levels and potentially reducing the risk of severe hypoglycemia in combination therapies.